Margarita Shafikova
Margarita Shafikova has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Konstantin V. Menshikov
Republican Clinical Oncology Dispensary; Bashkir State Medical University
3 shared publications - Natalia A. Sharafutdinova
Republican Clinical Oncology Dispensary, Ministry of Health of the Republic of Bashkortostan
3 shared publications - Shamil I. Musin
Republican Clinical Oncology Dispensary, Ufa, Russia
3 shared publications - Timerlan R. Baimuratov
Republican Clinical Oncological Dispensary, Ministry of Health of the Republic of Bashkortostan
3 shared publications - Sergei V. Osokin
Republican Clinical Oncological Dispensary, Ministry of Health of the Republic of Bashkortostan
2 shared publications - Vasily Ilyin
Republican Clinical Oncological Dispensary, Ministry of Health of the Republic of Bashkortostan
2 shared publications
Latest Publications
- 20 November 2026
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 16 (3)
De-escalation of neoadjuvant chemotherapy in resectable oral squamous cell carcinoma: results of a comparative analysis of DC and DCF modes
Introduction. The three-drug regimen consisting of docetaxel, cisplatin, and 5-fluorouracil (DCF) has traditionally been regarded as one of the most active neoadjuvant chemotherapy regimens for locally advanced head and neck squamous cell carcinoma. However, its use is associated with a high incidence of treatment-related adverse events. Therefore, the two-drug regimen of docetaxel plus cisplatin (DC) may represent a potential treatment de-escalation strategy for patients with initially resectable oral squamous cell carcinoma. Aim. To compare the short-term antitumor efficacy and toxicity profile of two- versus three-drug taxane-platinum neoadjuvant chemotherapy regimens in patients with resectable locally advanced oral squamous cell carcinoma. Materials and methods. This single-center retrospective cohort study included 45 patients with resectable locally advanced oral squamous cell carcinoma who received neoadjuvant chemotherapy followed by surgery between 2020 and 2026. Twenty-eight patients (62.2 %) received the DCF regimen, whereas 17 (37.8 %) received the DC regimen. Radiological response was assessed according to Response Evaluation Criteria in Solid Tumors 1.1. Pathologic response was classified as pathologic complete response, major pathologic response, or unfavorable pathologic response. Treatment-related toxicity was evaluated using the Common Terminology Criteria for Adverse Events, version 5.0. All patients received primary prophylaxis against chemotherapy-induced neutropenia with epegfilgrastim. Results. The objective response rate was 58.8 % in the DC group and 53.6 % in the DCF group (p = 0.767), whereas disease control rates were 100 and 89.3 %, respectively (p = 0.279). Tumor downstaging (reduction in T category) was observed in 64.7 and 64.3 % of patients, respectively (p = 1.000), while nodal downstaging (reduction in N category) occurred in 17.6 and 21.4 %, respectively (p = 1.000). The complete pathologic response rate was 11.8 % in the DC group and 10.7 % in the DCF group (p = 0.990), whereas the favorable pathologic response rate (complete pathologic response + major pathologic response) was 41.2 and 39.3 %, respectively (p = 1.000). R0 resection was achieved in all patients. Grade 3 adverse events occurred more frequently in the DCF group than in the DC group (53.6 % vs 17.6 %, p = 0.028), primarily because of a higher incidence of grade 3 non-hematological toxicity (42.9 % vs 5.9 %, p = 0.015). No cases of febrile neutropenia were observed. Conclusion. Among patients with resectable locally advanced oral squamous cell carcinoma, no statistically significant differences were observed between the DC and DCF regimens regarding objective response, disease control, tumor and nodal downstaging, pathologic response, or R0 resection rates. The DC regimen was associated with a significantly lower incidence of grade 3 adverse events, primarily owing to reduced non-hematological toxicity. These findings suggest that DC may represent a potential treatment de-escalation strategy for patients with initially resectable oral squamous cell carcinoma.
- 20 November 2026
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 16 (3)
De-escalation of neoadjuvant chemotherapy in resectable oral squamous cell carcinoma: results of a comparative analysis of DC and DCF modes
Introduction. The three-drug regimen consisting of docetaxel, cisplatin, and 5-fluorouracil (DCF) has traditionally been regarded as one of the most active neoadjuvant chemotherapy regimens for locally advanced head and neck squamous cell carcinoma. However, its use is associated with a high incidence of treatment-related adverse events. Therefore, the two-drug regimen of docetaxel plus cisplatin (DC) may represent a potential treatment de-escalation strategy for patients with initially resectable oral squamous cell carcinoma. Aim. To compare the short-term antitumor efficacy and toxicity profile of two- versus three-drug taxane-platinum neoadjuvant chemotherapy regimens in patients with resectable locally advanced oral squamous cell carcinoma. Materials and methods. This single-center retrospective cohort study included 45 patients with resectable locally advanced oral squamous cell carcinoma who received neoadjuvant chemotherapy followed by surgery between 2020 and 2026. Twenty-eight patients (62.2 %) received the DCF regimen, whereas 17 (37.8 %) received the DC regimen. Radiological response was assessed according to Response Evaluation Criteria in Solid Tumors 1.1. Pathologic response was classified as pathologic complete response, major pathologic response, or unfavorable pathologic response. Treatment-related toxicity was evaluated using the Common Terminology Criteria for Adverse Events, version 5.0. All patients received primary prophylaxis against chemotherapy-induced neutropenia with epegfilgrastim. Results. The objective response rate was 58.8 % in the DC group and 53.6 % in the DCF group (p = 0.767), whereas disease control rates were 100 and 89.3 %, respectively (p = 0.279). Tumor downstaging (reduction in T category) was observed in 64.7 and 64.3 % of patients, respectively (p = 1.000), while nodal downstaging (reduction in N category) occurred in 17.6 and 21.4 %, respectively (p = 1.000). The complete pathologic response rate was 11.8 % in the DC group and 10.7 % in the DCF group (p = 0.990), whereas the favorable pathologic response rate (complete pathologic response + major pathologic response) was 41.2 and 39.3 %, respectively (p = 1.000). R0 resection was achieved in all patients. Grade 3 adverse events occurred more frequently in the DCF group than in the DC group (53.6 % vs 17.6 %, p = 0.028), primarily because of a higher incidence of grade 3 non-hematological toxicity (42.9 % vs 5.9 %, p = 0.015). No cases of febrile neutropenia were observed. Conclusion. Among patients with resectable locally advanced oral squamous cell carcinoma, no statistically significant differences were observed between the DC and DCF regimens regarding objective response, disease control, tumor and nodal downstaging, pathologic response, or R0 resection rates. The DC regimen was associated with a significantly lower incidence of grade 3 adverse events, primarily owing to reduced non-hematological toxicity. These findings suggest that DC may represent a potential treatment de-escalation strategy for patients with initially resectable oral squamous cell carcinoma.
- Open Access
- 18 March 2026
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 15 (4) , 108-115
Biopsy of the sentinel lymph nodes in early oral cancer: literature review
Biopsy of the sentinel lymph nodes is a modern technique of surgical staging of head and neck tumors. It allows to determine advisability of cervical lymph node dissection in patients with early-stage oral cancer. The article presents a literature review on the history, methodology, and clinical efficacy of sentinel lymph node biopsy. It is shown that technological development and implementation of new indicators increase method efficacy, minimizing unnecessary surgical interventions and decreasing the risk of complications.
- 18 March 2026
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 15 (4) , 108-115
Open AccessBiopsy of the sentinel lymph nodes in early oral cancer: literature review
Biopsy of the sentinel lymph nodes is a modern technique of surgical staging of head and neck tumors. It allows to determine advisability of cervical lymph node dissection in patients with early-stage oral cancer. The article presents a literature review on the history, methodology, and clinical efficacy of sentinel lymph node biopsy. It is shown that technological development and implementation of new indicators increase method efficacy, minimizing unnecessary surgical interventions and decreasing the risk of complications.